Get the Stockscreener App
2.5025
5.11%
-0.1375
Metagenomi Inc stock is traded at $2.5025, with a volume of 569.20K.
It is down -5.11% in the last 24 hours and down -24.08% over the past month.
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
See More
Previous Close:
$2.64
Open:
$2.61
24h Volume:
569.20K
Relative Volume:
0.26
Market Cap:
$93.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.87%
1M Performance:
-24.08%
6M Performance:
-29.63%
1Y Performance:
+0.00%
1-Day Range:
$2.46
$2.67
1-Week Range:
$2.4331
$2.86
52-Week Range:
$1.61
$12.74
Metagenomi Inc Stock (MGX) Company Profile
Name
Metagenomi Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
2.505 | 93.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.08 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.65 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.08 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.38 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.36 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Inc Stock (MGX) Latest News
Analysts review Metagenomi Inc’s rating - Knox Daily
Is Metagenomi Inc (MGX) worth investing in despite its overvalued state? - US Post News
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Market Watch Highlights: Metagenomi Inc (MGX) Ends on an Downturn Note at 2.69 - The Dwinnex
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential - Seeking Alpha
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer - GlobeNewswire Inc.
The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26% - Simply Wall St
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Brokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $16.67 - MarketBeat
Stargate Project’s healthcare winners: AI-led biotechs and Metagenomi - MSN
FINAL REMINDER MGX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Metagenomi, Inc. Investors to Participate in the Class Action Lawsuit! - ACCESS Newswire
StockWatch: Up-to-$500B AI Venture Sparks Investor Interest, and Questions - Genetic Engineering & Biotechnology News
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
People are buying the wrong stock thinking it's part of OpenAI's Stargate Project - Quartz
Metagenomi aiming for clinical trials of gene-editing therapy in 2026 - Hemophilia News Today
Metagenomi outlines anticipated 2025 milestones - MSN
Metagenomi advances gene editing therapies into 2025 - Investing.com
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones - GlobeNewswire
Metagenomi Announces New Appointment to its Board of Directors - GlobeNewswire
Metagenomi, Inc. Announces Appointment of Eric Bjerkholt to Its Board of Directors, Serving on Audit and Compensation Committees, Effective January 27, 2025 - Marketscreener.com
Metagenomi, Inc.'s (NASDAQ:MGX) market cap dropped US$12m last week; individual investors who hold 33% were hit as were institutions - Yahoo Finance
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully - Simply Wall St
Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX) - MSN
Geode Capital Management LLC Has $734,000 Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Metagenomi CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Metagenomi: Q3 Earnings Snapshot - Marketscreener.com
Metagenomi, Inc. (NASDAQ:MGX) Short Interest Up 445.1% in December - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Shares Purchased by BNP Paribas Financial Markets - Defense World
Verition Fund Management LLC Makes New Investment in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - The Eastern Progress Online
MGX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In MGX To Contact Him Directly To Discuss Their Options - The Eastern Progress Online
2 ‘Monster’ Stocks to Snap Up Before 2025 - MSN
Metagenomi (NASDAQ:MGX) Price Target Raised to $14.00 - Defense World
MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Eastern Progress Online
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference 'RNA at the Bench and Bedside IV” - The Manila Times
Metagenomi Presents Highly Specific and Efficient Genome - GlobeNewswire
Metagenomi, Inc. Presents Highly Specific and Efficient Genome Editing Tools At Nature Conference RNA At the Bench and Bedside IV - Marketscreener.com
Metagenomi, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Metagenomi Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Metagenomi Inc Stock (MGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wapnick Pamela | Chief Financial Officer |
Sep 05 '24 |
Sale |
2.88 |
6,265 |
18,043 |
63,051 |
| Novo Holdings A/S | 10% Owner |
Feb 13 '24 |
Buy |
15.00 |
800,000 |
12,000,000 |
1,739,175 |
| Novo Holdings A/S | 10% Owner |
Feb 09 '24 |
Buy |
10.25 |
100,000 |
1,025,000 |
100,000 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):